| 1. A randomized, double-blind
parallel group study of the efficacy
and safety of an emollient formulation
of ammonium lactate 12% and 30%
creams (BMS-186091) versus their
vehicle in the treatment of signs
associated with photo damage
(Trial 1) – clinical study no
E109-024-006 12-94 – 8-95
2. A randomized double-blind, parallel
group study of the safety and efficacy
of LacHydrin 12% cream, (W1001-C-12) versus its vehicle in diabetic subjects
with dry skin. Clinical
study no. DE109-032-007. 10-95 – 3-96
3. An open-label, non-controlled safety
and efficacy study of BMS-181158/181159
solution (2% 4-Hydroxyanisole/0.1% tretinoin) in the treatment of solar lentigines
and related hyperpigmented
lesions. Clinical study no DE132-009-002
1-96 – 10-96
4. A randomized, double blind parallel
group study of the efficacy and
safety of Tazarotene in the treatment of Acne Vulgaris. Allergan Clinical Study
no. 190168-027P 6-97 – 6-98
5. A randomized, double blind parallel
group study of the efficacy and
safety of Tazarotene in the treatment
of Psoriasis. Allergan Clinical
Study no 190168-026P 6-97 – 6-98
6. A randomized, double-blind
parallel group study of the
efficacy and safety of LF43tip
Biogen monoclromal antibody 2-98 – 2-99 |
